Ironwood Pharmaceuticals, Inc.
IRWDNASDAQHealthcare● Active
$3.28
$-0.03(-0.91%)
Market Cap$539930640
P/E Ratio—
52W High$5.78
52W Low$0.56
Ironwood Pharmaceuticals, Inc. (IRWD) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IRWD · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.30B | $0.35B | $0.44B | $0.41B | $0.41B |
| Cost of Revenue | $0.00B | $0.01B | $0.01B | $0.00B | $0.07B |
| Gross Profit | $0.30B | $0.34B | $0.44B | $0.41B | $0.34B |
| Gross Margin %(computed) | 100.00% | 97.85% | 98.61% | 99.65% | 82.98% |
| Operating Expenses | |||||
| R&D Expenses | $0.10B | $0.11B | $0.12B | $0.04B | $0.07B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.18B | $0.25B | $1.38B | $0.16B | $0.11B |
| Operating Income | $0.12B | $0.09B | ($0.95B) | $0.25B | $0.23B |
| Operating Margin %(computed) | 40.10% | 26.50% | -213.54% | 60.97% | 56.13% |
| Interest Income | $0.00B | $0.00B | $0.02B | $0.01B | $0.00B |
| Interest Expense | $0.03B | $0.03B | $0.02B | $0.01B | $0.03B |
| Income Before Tax | $0.07B | $0.07B | ($0.95B) | $0.25B | $0.20B |
| Income Tax Expense | $0.05B | $0.06B | $0.08B | $0.08B | ($0.33B) |
| Net Income | $0.02B | $0.00B | ($1.00B) | $0.18B | $0.53B |
| Net Margin %(computed) | 8.11% | 0.25% | -226.37% | 42.64% | 127.72% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.15 | $0.01 | $-6.45 | $1.13 | $3.26 |
| Wtd Avg Shares | 0.16B | 0.16B | 0.16B | 0.15B | 0.16B |
| EBITDA | $0.10B | $0.10B | $0.20B | $0.26B | $0.23B |
| EBITDA Margin %(computed) | 35.34% | 27.81% | 44.59% | 63.67% | 56.49% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Ironwood Pharmaceuticals, Inc. data
About Ironwood Pharmaceuticals, Inc. (IRWD) Income Statement
Ironwood Pharmaceuticals, Inc. (IRWD) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, IRWD reported revenue of $0.30B, gross profit of $0.30B (gross margin 100.00%), and net income of $0.02B — a net profit margin of 8.11%.
Frequently asked questions
IRWD · 4 questionsIronwood Pharmaceuticals, Inc. (IRWD) reported revenue of $0.30B for 2025, down 15.7% year-over-year.
IRWD revenueIRWD salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08